Immunosuppresseurs dans la prévention de la réaction du greffon contre l'hôte : rapport de la SFGM-TC

[fr] Dans une démarche qui vise à unifonniser les procédures d'allogreffe de cellules souches hématopoïétiques (CSH), la Société française de greffe de moelle et de thérapie cellulaire (SFGM-TC), a organisé les quatrièmes ateliers d'harmonisation des pratiques en septembre 2013 à Lille. Dans cet atelier nous abordons les immunosuppresseurs utilisés dans la prévention de la réaction du greffon contre l'hôte: rapport de la SFGM-TC.
[en] In the attempt to harmonize dinical practîces between different French transplantation centers, the Frenell Society of Bane Marrow Transplantation and Cell Therapy (SFGM-TC) set up the fourth annual series of workshops which brought together practitioners from all member centers and taak place in September 2013 in Lille. Here we report our recommendatÎons regarding the use of immunosuppressive treatment in the prevention of graft versus hast disease: repOlt by the SFGM-TC.

Disciplines :

Hematology

Author, co-author :

Belaiche, S.

Yafour, N.

Balcaen, S.

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Borel, C.

Bruno, B.

Godin, S.

Labussière-Wallet, H.

Sanhamut, N.

Charbonnier, A.

More authors (4 more)

Language :

French

Title :

Immunosuppresseurs dans la prévention de la réaction du greffon contre l'hôte : rapport de la SFGM-TC

Alternative titles :

[en] Utilisation of immunosuppressants in the prevention of a graft versus host reaction : report by the SFGM-TC

Publication date :

2014

Journal title :

Pathologie Biologie

ISSN :

0369-8114

eISSN :

1768-3114

Publisher :

Elsevier, Paris, France

Volume :

Pages :

197-203

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 October 2014

Statistics

Number of views

93 (6 by ULiège)

Number of downloads

693 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Storb R., Antin J.H., Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. Biol Blood Marrow Transplant 2010, 16(1Suppl.):S18-S27.
Hiraoka A., Ohashi Y., Okamoto S., Moriyama Y., Nagao T., Kodera Y., et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001, 28(2):181-185.
Nash R.A., Antin J.H., Karanes C., Fay J.W., Avalos B.R., Yeager A.M., et al. Phase 3study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96(6):2062-2068.
Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009, 43(8):643-653.
Storb R., Yu C., Wagner J.L., Deeg H.J., Nash R.A., Kiem H.P., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89(8):3048-3054.
Atkinson K., Downs K. Omission of day 11methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant 1995, 16(6):755-758.
Kumar S., Wolf R.C., Chen M.G., Gastineau D.A., Gertz M.A., Inwards D.J., et al. Omission of day +11methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002, 30(3):161-165.
Ruutu T., Niederwieser D., Gratwohl A., Apperley J.F. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997, 19(8):759-764.
Niederwieser D., Maris M., Shizuru J.A., Petersdorf E., Hegenbart U., Sandmaier, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101(4):1620-1629.
Brissot E., Chevallier P., Guillaume T., Delaunay J., Ayari S., Dubruille V., et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2010, 45(4):786-788.
Takeuchi H., Matsuno N., Hirano T., Toraishi T., Konno O., Nakamura Y., et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2level and tacrolimus by trough level. Transplant Proc 2008, 40(7):2240-2242.
Nemati E., Einollahi B., Taheri S., Moghani-Lankarani M., Kalantar E., Simforoosh N., et al. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss?. Transplant Proc 2007, 39(4):1223-1224.
Malard F., Szydlo R.M., Brissot E., Chevallier P., Guillaume T., Delaunay J., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16(1):28-34.
Willemze A.J., Press R.R., Lankester A.C., Egeler R.M., den Hartigh J., Vossen J.M. CsA exposure is associated with acute GVHD and relapse in children after SCT. Bone Marrow Transplant 2010, 45(6):1056-1061.
Schieven P.G.V., Royer B. Niveau de preuve du suivi thérapeutique pharmacologique de l'acide mycophénolique administré pour la prévention des réactions du greffon contre l'hÔte au cours des greffes de cellules souches avec un conditionnement réduit. Therapie 2011, 66(1):5.
Haentzschel I., Freiberg-Richter J., Platzbecker U., Kiani A., Schetelig J., Illmer T., et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 2008, 42(2):113-120.
Ng J., Rogosheske J., Barker J., Weisdorf D., Jacobson P.A. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 2006, 28(3):394-401.
Wakahashi K., Yamamori M., Minagawa K., Ishii S., Nishikawa S., Shimoyama, et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol 2011, 94(2):193-202.
Finke J., Bethge W.A., Schmoor C., Ottinger H.D., Stelljes M., Zander, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3trial. Lancet Oncol 2009, 10(9):855-864.
Mohty M., Labopin M., Balère M.L., Socié G., Milpied N., Tabrizi R., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Société française de greffe de moelle et de thérapie cellulaire. Leukemia 2010, 24(11):1867-1874.
Socié G., Schmoor C., Bethge W.A., Ottinger H.D., Stelljes M., Zander A.R., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117(23):6375-6382.
Bacigalupo A., Lamparelli T., Bruzzi P., Guidi S., Alessandrino P.E., di Bartolomeo P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98(10):2942-2947.
Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Haematol 2008, 21(2):177-192.
Krejci K., Tichy T., Bachleda P., Zadrazil J. Calcineurin inhibitor-induced renal allograft nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010, 154(4):297-306.
Interactions médicamenteuses-Le guide prescrire 2013. Rev Prescrire 2012, 32(supplément 350):560.
Bay J.O., Dalle J.H., Dhedin N., Turlure P., Cornillon J., Balcaen S., et al. Prophylaxie de la réaction aiguë du greffon contre l'hÔte. Hematologie 2011, 17(supplement 3):2.
Claviez A., Glass B., Dreger P., Suttorp M. Elevated blood drug levels obtained from indwelling silicon catheters during oral cyclosporine A administration. Bone Marrow Transplant 2002, 29(6):535-536.
Donnelly J.P., Blijlevens N.M., Schattenberg A.V. Monitoring cyclosporine using blood drawn via a central venous catheter. Bone Marrow Transplant 2003, 32(10):1037.
Krejci K., Tichy T., Bachleda P., Zadrazil J. Calcineurin inhibitor-induced renal allograft nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011, 154(4):297-306.
Claes K., Meier-Kriesche H.U., Schold J.D., Vanrenterghem Y., Halloran P.F., Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2011, 27(2):850-857.
Arnold R., Pussell B.A., Pianta T.J., Lin C.S., Kiernan M.C., Krishnan A.V. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 2013, 13(9):2426-2432.
Bechstein W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000, 13(5):313-326.
Claes K., Meier-Kriesche H.U., Schold J.D., Vanrenterghem Y., Halloran P.F., Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012, 27(2):850-857.
Arnold R., Pussell B.A., Pianta T.J., Lin C.S., Kiernan M.C., Krishnan A.V. Association Between Calcineurin Inhibitor Treatment and Peripheral Nerve Dysfunction in Renal Transplant Recipients. Am J Transplant 2013.